5 Ways to Recruit Badly Needed Patients for Alzheimer’s Disease Clinical Trials Involving Therapies

Nearly 20 years of research have resulted in a single FDA-approved drug for the treatment of Alzheimer’s disease. And even this isolated therapy, aducanumab (Aduhelm), has struggled to gain widespread confidence in its effectiveness.

According to a multidisciplinary panel, the main issue is the clinical rigor of the research. But the problem is not with the science per se. It is in need of many more participating patients.

Demand is especially high, the team notes, for asymptomatic people of all races and ethnicities.

This month, the panel – which engaged representatives from academia, patient advocacy organizations, philanthropy, nonprofits, government and industry – released a detailed analysis of the opportunity in Alzheimer’s and dementiathe official journal of the Alzheimer’s Association [1].

More needs to be done to attract participants, they suggest, because clinical trials in Alzheimer’s disease are not only slower to recruit subjects, but also cost more and take longer than trials in many others. therapeutic areas, if not most.

The corresponding author of the article is health economist Julie Zissimopoulos, PhD, of the University of Southern California. The lead author is USC neurologist Paul Aisen, MD.

The article includes a comprehensive set of recommendations aimed at addressing key patient recruitment challenges faced by researchers who wish to conduct robust clinical trials of Alzheimer’s disease treatments.

Here are examples of recommendations in five of the eight categories described by the authors.

Back To Top